Summary:
- The article discusses a planned mRNA gene therapy against respiratory syncytial virus (RSV) called mRESVIA mRNA 1345.
- It expresses concerns about the safety and potential risks of this mRNA vaccine, citing the need for more thorough testing and evaluation before it is approved and administered.
- The article calls for an immediate halt to the development and rollout of this mRNA vaccine, arguing that the potential risks outweigh the benefits.